Similar articles

• The role of somatostatin analogs in the treatment of endocrine gastrointestinal tumors.

  Trautmann ME, Neuhaus C, Lenze H, Benning R, Benning M, Dennler HJ, Bruns C, Joseph K, Arnold R. Trautmann ME, et al. Horm Metab Res Suppl. 1993;27:24-7. Horm Metab Res Suppl. 1993. PMID: 8392487 Clinical Trial. No abstract available.
• Management of gastroenteropancreatic endocrine tumors: the place of somatostatin analogues.

  Arnold R, Frank M, Kajdan U. Arnold R, et al. Digestion. 1994;55 Suppl 3:107-13. doi: 10.1159/000201211. Digestion. 1994. PMID: 7698532 Review.
• [Use of octreotide in the treatment of digestive endocrine tumors. A French multicenter study].

  Blanchin M, James-Deidier A, Chaumet-Riffaud PD, Chayvialle JA. Blanchin M, et al. Presse Med. 1992 Apr 18;21(15):697-702. Presse Med. 1992. PMID: 1376476 Clinical Trial. French.
• Octreotide--a synthetic somatostatin.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 1989 Jul 14;31(796):66-8. Med Lett Drugs Ther. 1989. PMID: 2567960 Clinical Trial. No abstract available.
• [Clinical applications of octreotide in gastro-entero-pancreatic (GEP) tumors].

  Arnold R, Neuhaus C, Trautmann M. Arnold R, et al. Z Gastroenterol. 1990 Sep;28 Suppl 2:22-8. Z Gastroenterol. 1990. PMID: 1980774 Review. German. No abstract available.